Raphael Pharmaceutical (RAPH) Long-Term Deferred Tax (2020 - 2025)

Raphael Pharmaceutical (RAPH) has 6 years of Long-Term Deferred Tax data on file, last reported at $8.8 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax rose 26.81% year-over-year to $8.8 million; the trailing twelve-month figure through Dec 2025 stood at $8.8 million (up 26.81% YoY), and the FY2025 full-year result was $8.8 million, up 26.81% from the prior year.
• Long-Term Deferred Tax advanced to $8.8 million in Q4 2025, from $7.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $8.8 million in Q4 2025 to a low of $3.2 million in Q4 2022.
• A 5-year average of $6.1 million and a median of $5.7 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax surged 736.39% in 2021 and plunged 44.31% in 2022, its largest moves.
• Tracing RAPH's Long-Term Deferred Tax over 5 years: stood at $5.7 million in 2021, then sank by 44.31% to $3.2 million in 2022, then surged by 79.41% to $5.7 million in 2023, then grew by 21.32% to $7.0 million in 2024, then grew by 26.81% to $8.8 million in 2025.
• Business Quant data shows RAPH's Long-Term Deferred Tax at $8.8 million in Q4 2025, $7.0 million in Q4 2024, and $5.7 million in Q4 2023.